PROFILE OF STABLE COPD PATIENTS IN COUNTRIES FROM CENTRAL EASTERN EUROPE: RESULTS FROM A LARGE OBSERVATIONAL STUDY

Abstract

SESSION TITLE: Tuesday Abstract Posters SESSION TYPE: Original Investigation Posters PRESENTED ON: 10/22/2019 01:00 PM - 02:00 PM PURPOSE: The profile of patients with stable chronic obstructive pulmonary disease (COPD) in countries from Central Eastern Europe (CEE) is not clearly characterized. The population of stable COPD patients from 5 CEE countries participating in a large cross-sectional observational study is described here. METHODS: In a multinational study (NCT03031769), 2162 patients with stable COPD were enrolled from in 11 participating countries. In total, 1422 patients were enrolled from CEE: Romania (RO) n=406, Poland (PL) n=356, Serbia (SB) n=250, Bulgaria (BG) n=210 and Slovakia (SK) n=200. Eligible patients were aged ≥40 years with ≥1 year since COPD diagnosis. All patients were current or former smokers with a smoking history of ≥10 pack-years (PY). Stable disease was defined as no exacerbation history or changes in COPD maintenance treatment in last 2 months before enrolment. Exacerbation was defined as acute worsening of respiratory symptoms resulting in additional therapy. RESULTS: The mean age was 65.9 years in RO, 66.6 in SK, 66.7 in BG, 67.0 in PL and 68.0 in SB. More males were enrolled, from 61.0% in PL to 78.5% in SK and 83.5% in RO. Mean tobacco consumption (PY) for both smokers and non-smokers was 32.2 in BG, 32.5 in SK, 36.4 in PL, 38.1 in RO and 41.9 in SB. Mean post-bronchodilator FEV1 varied from 45.0% in BG and 47.8% in RO to 54.1% in PL, 54.5% in SK and 60.7% in SB. Most patients had moderate to severe airflow obstruction – percentages of patients ranged from 80.0% in SB, 83.7% in RO, 84.3% in BG, 87.7% in PL and 90.0% in SK. Mean number of exacerbations/patient in the last year (mild, moderate and severe) was 0.7 in SK, 1.9 in RO, 3.5 in BG, 4.8 in PL and 6.3 in SB. SB had the highest percentage of patients reporting severe exacerbations in last year (58.8%), while BG had highest percentage of patients with moderate exacerbations in last year (51.4%). Mean number of visits/year to chest specialist was 2.3 in BG, 3.4 in RO, 3.5 in SB, 3.7 in PL and 4.7 in SK. Mean score of COPD Assessment Test (CAT) ranged from 15 in SK and SB to almost 17 in PL, 19 in RO and 19.2 in BG. The distribution of low burden (A/C) vs. high burden (B/D) symptom categories by GOLD 2017 report differed at country level: 27.2% vs. 72.8% in BG, 35.9% vs. 64.1% in PL, 27.6% vs. 72.4% in RO, 32.5% vs. 67.5% in SK and 48.4% vs. 51.6% in SB. CONCLUSIONS: More discrepancies than similarities in characteristics of stable COPD patients were found across CEE countries participating in this study. The cultural, environmental and healthcare system differences may partly explain the results found. CLINICAL IMPLICATIONS: This large study allowed the homogeneous collection of data from 5 CEE countries. The variability of characteristics of stable COPD patients across countries may be explained by personal factors and local treatment and monitoring aspects that require further exploration. DISCLOSURES: Employee relationship with AstraZeneca Please note: $1001 - $5000 Added 03/10/2019 by Silviu Alecu, source=Web Response, value=Salary No relevant relationships by Adam Antczak, source=Web Response Employee relationship with AstraZeneca Please note: $1001 - $5000 Added 03/14/2019 by Yunqin Chen, source=Web Response, value=Salary No relevant relationships by Florin Mihaltan, source=Web Response No relevant relationships by Vesna Radulović, source=Web Response